Ross W. Newman will speak at the NevBio meeting on September 11, 2013. He began his 30+ year career in pharmaceutical/biotech research working as a West Coast correspondent of the investment banking firm Allen & Co. In that role, he directed capital into-and sat on the board of directors of-many early biotech start-ups developed from research coming out of the University of California, San Francisco and Stanford University. As one of the start-ups was failing, he was selected by the board to become the company's new CEO. Newman was just in his 20's when he directed the shut-down and merger into Xoma, Inc. of one of the first monoclonal antibody companies in the country to go into clinical trials and fail. Early in his career, he lost a couple million dollars of his own money (most of which was borrowed, he says) and close to $20 million of investor money. It took until 1996 to pay off his debt. Newman earned a BA in Political Demography from the University of California, Berkeley in 1971. After graduating, he traveled. In 1973, he returned to Berkeley where he completed his doctoral dissertation in epistemology in 1977.